Journal of Medicinal Chemistry
Page 12 of 13
Cholangiocarcinoma Identified through Broad-Based Tumor
Genotyping. The Oncologist 2012, 17 (1), 72–79.
14) Ward, P. S.; Patel, J.; Wise, D. R.; Abdel-Wahab, O.; Bennett, B.
D.; Coller, H. A.; Cross, J. R.; Fantin, V. R.; Hedvat, C. V.; Perl, A. E.;
Rabinowitz, J. D.; Carroll, M.; Su, S. M.; Sharp, K. A.; Levine, R. L.;
Thompson, C. B. The Common Feature of Leukemia-Associated
IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity
Converting α-Ketoglutarate to 2-Hydroxyglutarate. Cancer Cell
(24) Cho, Y. S.; Levell, J. R.; Liu, G.; Caferro, T.; Sutton, J.; Shafer, C.
1
2
3
4
5
6
7
8
9
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
5
5
5
5
5
5
5
5
5
5
6
M.; Costales, A.; Manning, J. R.; Zhao, Q.; Sendzik, M.; Shultz, M.;
Chenail, G.; Dooley, J.; Villalba, B.; Farsidjani, A.; Chen, J.; Kulathila,
R.; Xie, X.; Dodd, S.; Gould, T.; Liang, G.; Heimbach, T.; Slocum, K.;
Firestone, B.; Pu, M.; Pagliarini, R.; Growney, J. D. Discovery and
Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant
IDH1 Inhibitor. ACS Med. Chem. Lett. 2017, 8 (10), 1116–1121.
(25) Burris, H.; Mellinghoff, I.; Maher, E.; Wen, P.; Beeram, M.;
Touat, M.; Faris, J.; Azad, N.; Cloughesy, T.; Gore, L.; Trent, J.; Hoff,
D. V.; Goldwasser, M.; Fan, B.; Agresta, S. Abstract PL04-05: The
First Reported Results of AG-120, a First-in-Class, Potent Inhibitor
of the IDH1 Mutant Protein, in a Phase I Study of Patients with
Advanced IDH1-Mutant Solid Tumors, Including Gliomas. Mol.
Cancer Ther. 2015, 14 (12 Supplement 2), PL04-05-PL04-05.
(26) Fan, B.; Le, K.; Manyak, E.; Liu, H.; Prahl, M.; Bowden, C. J.;
(
2
010, 17 (3), 225–234.
(
15) Abbas, S.; Lugthart, S.; Kavelaars, F. G.; Schelen, A.; Koenders,
J. E.; Zeilemaker, A.; van Putten, W. J. L.; Rijneveld, A. W.;
Löwenberg, B.; Valk, P. J. M. Acquired Mutations in the Genes
Encoding IDH1 and IDH2 Both Are Recurrent Aberrations in Acute
Myeloid Leukemia: Prevalence and Prognostic Value. Blood 2010,
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
2
3
4
5
6
7
8
9
0
1
16 (12), 2122–2126.
(
16) Paschka, P.; Schlenk, R. F.; Gaidzik, V. I.; Habdank, M.; Kronke,
Biller,
S.;
Agresta,
S.;
Yang,
H.
Longitudinal
J.; Bullinger, L.; Spath, D.; Kayser, S.; Zucknick, M.; Gotze, K.; Horst,
H.-A.; Germing, U.; Dohner, H.; Dohner, K. IDH1 and IDH2 Mutations
Are Frequent Genetic Alterations in Acute Myeloid Leukemia and
Confer Adverse Prognosis in Cytogenetically Normal Acute
Myeloid Leukemia With NPM1 Mutation Without FLT3 Internal
Tandem Duplication. J. Clin. Oncol. 2010, 28 (22), 3636–3643.
Pharmacokinetic/Pharmacodynamic Profile of AG-120, a Potent
Inhibitor of the IDH1 Mutant Protein, in a Phase 1 Study of IDH1-
Mutant Advanced Hematologic Malignancies. Blood 2015, 126
(23), 1310–1310.
(27) Fan, B.; Goyal, L.; Lowery, M. A.; Pandya, S. S.; Manyak, E.; Le,
K.; Jiang, L.; Auer, J.; Dai, D. Pharmacokinetic/Pharmacodynamic
(PK/PD) Profile of AG-120 in Patients with IDH1-Mutant
Cholangiocarcinoma from a Phase 1 Study of Advanced Solid
Tumors. J. Clin. Oncol. 2017, 35 (15_suppl), 4082–4082.
(28) Watts, J.; Baer, M. R.; Yang, J.; Dinner, S.; Lee, S.; Seiter, K.;
Prebet, T.; Schiller, G. J.; Ferrell, P. B.; Dao, K.-H.; Kantarjian, H. M.;
Kelly, P.; Li, P.; Sweeney, J.; Watson, C.; Mohamed, H.; Cortes, J. E.
Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in
Patients with IDH1m Acute Myeloid Leukemia (AML) or
Myelodysplastic Syndrome (MDS). Blood 2018, 132 (Suppl 1),
1453–1453.
(29) Watts, J. M.; Baer, M. R.; Lee, S.; Yang, J.; Dinner, S. N.; Prebet,
T.; Schiller, G. J.; Seiter, K.; Ferrell, P. B.; Kelly, P. F.; Li, P.; Sweeney,
J.; Watson, C.; Mohamed, H.; Cortes, J. E. A Phase 1 Dose Escalation
Study of the IDH1m Inhibitor, FT-2102, in Patients with Acute
Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS). J.
Clin. Oncol. 2018, 36 (15_suppl), 7009–7009.
(30) Cortes, J. E.; Watts, J.; Prebet, T.; Schiller, G. J.; Lee, S.; Yang, J.;
Wang, E. S.; Dinner, S.; Ferrell, P. B.; Donnellan, W.; Jonas, B. A.; Wei,
A. H.; Montesinos, P.; Sangerman, M. A.; Kelly, P.; Li, P.; Sweeney, J.;
Watson, C.; Mohamed, H.; Baer, M. R. FT-2102, an IDH1m Inhibitor,
in Combination with Azacitidine in Patients with Acute Myeloid
Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results
from a Phase 1 Study. Blood 2018, 132 (Suppl 1), 1452–1452.
(31) Lin, J.; Lu, W.; Caravella, J.; Campbell, A.-M.; Diebold, R. B.;
Ericsson, A.; Fritzen, E.; Gustafson, G.; Lancia, D.; Wang, Z.; Castro,
J.; Clarke, A.; Gotur, D.; Josephine, H.; Katz, M.; Diep, H.; Kershaw,
M.; Yao, L.; Kauffman, G.; Hubbs, S.; Luke, G.; Toms, A.; Wang, L.;
Bair, K.; Barr, K.; Dinsmore, C.; Walker, D.; Ashwell, S. Discovery and
Optimization of Quinoline Derivatives as Potent, Selective, and
Orally Bioavailable Mutant Isocitrate Dehydrogenase 1 Inhibitors.
J. Med. Chem. 2019.
(
17) Rohle, D.; Popovici-Muller, J.; Palaskas, N.; Turcan, S.;
Grommes, C.; Campos, C.; Tsoi, J.; Clark, O.; Oldrini, B.;
Komisopoulou, E.; Kunii, K.; Pedraza, A.; Schalm, S.; Silverman, L.;
Miller, A.; Wang, F.; Yang, H.; Chen, Y.; Kernytsky, A.; Rosenblum, M.
K.; Liu, W.; Biller, S. A.; Su, S. M.; Brennan, C. W.; Chan, T. A.; Graeber,
T. G.; Yen, K. E.; Mellinghoff, I. K. An Inhibitor of Mutant IDH1 Delays
Growth and Promotes Differentiation of Glioma Cells. Science
2
013, 340 (6132), 626–630.
(18) Popovici-Muller, J.; Saunders, J. O.; Salituro, F. G.; Travins, J. M.;
Yan, S.; Zhao, F.; Gross, S.; Dang, L.; Yen, K. E.; Yang, H.; Straley, K. S.;
Jin, S.; Kunii, K.; Fantin, V. R.; Zhang, S.; Pan, Q.; Shi, D.; Biller, S. A.;
Su, S. M. Discovery of the First Potent Inhibitors of Mutant IDH1
That Lower Tumor 2-HG in Vivo. ACS Med. Chem. Lett. 2012, 3 (10),
8
50–855.
(19) Zheng, B.; Yao, Y.; Liu, Z.; Deng, L.; Anglin, J. L.; Jiang, H.; Prasad,
B. V. V.; Song, Y. Crystallographic Investigation and Selective
Inhibition of Mutant Isocitrate Dehydrogenase. ACS Med. Chem.
Lett. 2013, 4 (6), 542–546.
(
20) Liu, Z.; Yao, Y.; Kogiso, M.; Zheng, B.; Deng, L.; Qiu, J. J.; Dong,
S.; Lv, H.; Gallo, J. M.; Li, X.-N.; Song, Y. Inhibition of Cancer-
Associated Mutant Isocitrate Dehydrogenases: Synthesis,
Structure-Activity Relationship, and Selective Antitumor Activity. J.
Med. Chem. 2014, 57 (20), 8307–8318.
(
21) Brooks, E.; Wu, X.; Hanel, A.; Nguyen, S.; Wang, J.; Zhang, J. H.;
Harrison, A.; Zhang, W. Identification and Characterization of
Small-Molecule Inhibitors of the R132H/R132H Mutant Isocitrate
Dehydrogenase
Heterodimer. J. Biomol. Screen. 2014, 19 (8), 1193–1200.
22) Deng, G.; Shen, J.; Yin, M.; McManus, J.; Mathieu, M.; Gee, P.; He,
1
Homodimer
and
R132H/Wild-Type
(
T.; Shi, C.; Bedel, O.; McLean, L. R.; Le-Strat, F.; Zhang, Y.; Marquette,
J.-P.; Gao, Q.; Zhang, B.; Rak, A.; Hoffmann, D.; Rooney, E.; Vassort,
A.; Englaro, W.; Li, Y.; Patel, V.; Adrian, F.; Gross, S.; Wiederschain,
D.; Cheng, H.; Licht, S. Selective Inhibition of Mutant Isocitrate
Dehydrogenase 1 (IDH1) via Disruption of a Metal Binding
Network by an Allosteric Small Molecule. J. Biol. Chem. 2015, 290
(32) Wager, T. T.; Hou, X.; Verhoest, P. R.; Villalobos, A. Moving
beyond Rules: The Development of a Central Nervous System
Multiparameter Optimization (CNS MPO) Approach To Enable
Alignment of Druglike Properties. ACS Chem. Neurosci. 2010, 1 (6),
435–449.
(33) Lin, J.; Ericsson, A.; Campbell, A.-M.; Gustafson, G.; Wang, Z.;
Diebold, R. B.; Ashwell, S.; Jr, D. R. L.; Caravella, J. A.; Lu, W. Pyridinyl
Quinolinone Derivatives as Mutant-Isocitrate Dehydrogenase
Inhibitors. US9771349B2, September 26, 2017.
(
(
2), 762–774.
23) Okoye-Okafor, U. C.; Bartholdy, B.; Cartier, J.; Gao, E. N.;
Pietrak, B.; Rendina, A. R.; Rominger, C.; Quinn, C.; Smallwood, A.;
Wiggall, K. J.; Reif, A. J.; Schmidt, S. J.; Qi, H.; Zhao, H.; Joberty, G.;
Faelth-Savitski, M.; Bantscheff, M.; Drewes, G.; Duraiswami, C.;
Brady, P.; Groy, A.; Narayanagari, S.-R.; Antony-Debre, I.; Mitchell,
K.; Wang, H. R.; Kao, Y.-R.; Christopeit, M.; Carvajal, L.; Barreyro, L.;
Paietta, E.; Makishima, H.; Will, B.; Concha, N.; Adams, N. D.;
Schwartz, B.; McCabe, M. T.; Maciejewski, J.; Verma, A.; Steidl, U.
New IDH1 Mutant Inhibitors for Treatment of Acute Myeloid
Leukemia. Nat. Chem. Biol. 2015, 11 (11), 878–886.
ACS Paragon Plus Environment